Xin Lang Cai Jing·2025-12-03 06:30Core Viewpoint - The news discusses ongoing investor compensation cases involving Haiyue Energy and Ningke Biological, highlighting legal actions taken due to financial misconduct and false reporting by these companies [1][3]. Group 1: Haiyue Energy (600387) - Haiyue Energy has been involved in a compensation case where investors have received settlements through mediation, with ongoing efforts to accept more claims [1][2]. - The company was penalized by the China Securities Regulatory Commission (CSRC) for failing to disclose non-operating fund occupation by its controlling shareholder, which was not reported in several financial statements [1][2]. - A significant accounting error was identified, where Haiyue Energy incorrectly used the total amount method to recognize revenue, leading to an inflated revenue and cost figure of 302,081.64 million yuan, which represented 49.33% and 50.51% of the reported figures respectively [2][8]. Group 2: Ningke Biological (600165) - Ningke Biological's investor compensation case has also progressed, with a court ruling in favor of investors, and the legal team is accepting more claims [3][9]. - The company was found to have falsely reported its 2022 annual revenue, inflating it by 7,659.41 million yuan, which accounted for 11.25% of the total revenue, and profit by 7,722.20 million yuan, representing 46.59% of the total profit [9][10]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of key subsidiary operations [10].